Suchergebnisse - "Keenan, Robert T"

PubPharm (19)

1

The COMPARE head-to-head, randomized controlled trial of SEL-212 (pegadricase plus rapamycin-containing nanoparticle, ImmTOR™) versus pegloticase for refractory gout

enthalten in: Rheumatology (Oxford, England) | 2024

von Baraf, H. | Khanna, P. | Kivitz, A. | +8

2

Pegloticase causes prolonged improvement in multiple disease parameters in patients with chronic refractory gout who maintain low serum urate levels

enthalten in: Clinical and experimental rheumatology | 2022

von Keenan, R. | Yeo, A. | Lipsky, P.

3

Expert Opinion on Pegloticase with Concomitant Immunomodulatory Therapy in the Treatment of Uncontrolled Gout to Improve Efficacy, Safety, and Durability of Response

enthalten in: Current rheumatology reports | 2022

von Botson, J. | Baraf, H. | Keenan, R. | +10

4

The effect of immunomodulators on the efficacy and tolerability of pegloticase : a systematic review

enthalten in: Seminars in arthritis and rheumatism | 2021

von Keenan, R. | Botson, J. | Masri, K. | +4

5

Colorectal Cancer Among Gout Patients Undergoing Colonoscopy

enthalten in: Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases | 2019

von Slobodnick, A. | Krasnokutsky, S. | Lehmann, R. | +4

6

Low-Dose Allopurinol Promotes Greater Serum Urate Lowering in Gout Patients with Chronic Kidney Disease Compared with Normal Kidney Function

enthalten in: Bulletin of the Hospital for Joint Disease (2013) | 2019

von Toprover, M. | Crittenden, D. | Modjinou, D. | +5

7

Pegloticase failure and a possible solution : Immunosuppression to prevent intolerance and inefficacy in patients with gout

enthalten in: Seminars in arthritis and rheumatism | 2017

von Berhanu, A. | Krasnokutsky, S. | Keenan, R. | +1

8

Lesinurad in combination with allopurinol : a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study)

enthalten in: Annals of the rheumatic diseases | 2017

von Bardin, T. | Keenan, R. | Khanna, P. | +7

CommentIn: Ann Rheum Dis. 2017 May;76(5):779-781. - PMID 28039184

9

Limitations of the Current Standards of Care for Treating Gout and Crystal Deposition in the Primary Care Setting : A Review

enthalten in: Clinical therapeutics | 2017

von Keenan, R.

10

New and Pipeline Drugs for Gout

enthalten in: Current rheumatology reports | 2016

von Keenan, R. | Schlesinger, N.